Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies

COVID-19 still represents a major issue for patients with lymphoid malignancies, especially those on therapy, because of immune suppression and suboptimal responses to vaccination. Davis et al report on their experience with double dose tixagevimab-cilgavimab preexposure prophylaxis in a cohort of 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, James A., Granger, Katelynn, Roubal, Kiera, Smith, Deidra, Gaffney, Kelly J., McGann, Mary, Cendagorta, Alyssa, Thurlapati, Aswani, Herbst, Amanda, Hendrickson, Lindsey, Hashmi, Hamza, Hess, Brian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by The American Society of Hematology 2023
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636601/
https://www.ncbi.nlm.nih.gov/pubmed/36332185
http://dx.doi.org/10.1182/blood.2022018283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636601/
https://www.ncbi.nlm.nih.gov/pubmed/36332185
http://dx.doi.org/10.1182/blood.2022018283

Ejemplares similares